Clinical Trial Update: Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating docetaxel or cabazitaxel with or without darolutamide in metastatic castration-resistant prostate cancer; currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Cabazitaxel (cabazitaxel)
• DOCETAXEL (DOCETAXEL)
• Darolutamide (darolutamide)

Snippet

Sponsor: Erasmus Medical Center | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 2 | Status: RECRUITING